Protagen’s established and committed investors support the company’s pioneering work in the fields of immuno-oncology and autoimmune disease, helping to advance the adoption of precision medicine approaches.
Protagen is proud to collaborate with its investors to help develop precision diagnostic tools for the benefit of patients, and is always looking at entering into new partnerships to help progress its research and commercialization efforts. If you are interested in investing in the company, please contact us.
Current investors and stakeholders
Protagen is proud to work with its investors to expand therapeutic development for immuno-oncology and autoimmune disease. Protagen’s current investors are:
- MIG Fonds
- KfW (Kreditanstalt für Wiederaufbau)
- S-Capital Dortmund
- S-Venture Capital
- Management & founders
If you are interested in investing in the company, please contact us.
Protagen’s corporate leadership team combines over 40 years of commercial expertise and experience within the biotechnology industry, with a background spanning immunology, oncology, biomarker discovery and more.
Protagen is currently setting up an international scientific advisory board with key opinion leaders from the immuno-oncology and autoimmune disease fields. These expert panels will support our efforts in engaging with the medical and scientific community to develop products that are aimed at market needs.
Protagen is dedicated to the development of powerful diagnostic tools that aid successful therapeutic development and facilitate improved treatment strategies in the areas of autoimmune disease and immuno-oncology.
Here you will find our quarterly newsletter, “Stratified News from Dortmund”. With our newsletter we intend to regularly update you on developments at Protagen in a fresh and colorful format and we hope that you like it.
Get in touch
Improving the treatment of cancer and autoimmune disease is our passion, and we always welcome the chance to discuss these topics with current and prospective customers, patients and clinicians alike.